(1547411) Minimal residual disease-guided combination of ibrutinib and venetoclax compared to FCR in untreated patients with CLL of intermediate risk : interim results of MRD kinetics in the ERADIC trial from the FILO group

Primary Author; Presenting Author(s)

• AM

  Anne-Sophie Michallet, MD, PhD

  Head of the Hematology Department
  Léon Bérard Cancer Center in Lyon (CLB)
  Lyon, France

  Slides

Co-Author(s)

• 

  Anne Quinquenel, MD, PhD

  Dr
  CHU Reims
  Reims, France
• RL

  Remi Letestu, MD

  MCU-PH
  Laboratoire d'Hématologie, Hôpital Avicenne, APHP
  Bobigny, France
• ML

  Magali Legarff-Tavernier, MD

  INSERM, UMR-S 945, AP-HP, Hôpital Pitié-Salpêtrière, Service d'Hématologie Biologique
  Paris, France
• FS

  Fabien Subtil, statisticien

  Université de Lyon 1, 69000 Lyon, France; Hospices civils de Lyon, service de biostatistiques
  Lyon, France
• TA

  Thérèse Aurran, MD

  Institut Paoli Calmettes
  Marseille, France
• KL

  Kamel Laribi, MD

  MD
  Hematology Department, Centre Hospitalier du Mans, Le Mans, France
• 

  Florence Cymbalista, MD, PhD

  Professor of Hematology
  Hôspital Avicienne
  Avicenne Hospital
  Bobigny, France
• VL

  Vincent Levy, MD, PhD

  head
  APHP, Université Sorbonne Paris Nord
  Bobigny, France
• LS

  Laurence Simon, MD

  Sorbonne Université, Service d'Hématologie Clinique, Hôpital Pitié-Salpêtrière, Assitance Publique des Hôpitaux de Paris (AP1HP)
  Paris, France
• DR

  Damien Roos Weill, MD, PhD

  Hematology Department, Pitie-Salpetriere Hospital
  Paris, France
• VL

  Veronique Leblond, MD, PhD

  Service Hématologie, Hôpital de la Pitié-Salpêtrière, APHP
  Paris, France
• MD

  Marie-Sarah Dilhuydy, MD

  CHU Bordeaux, France
• CT

  Cecile Tomowiak, MD

  Hospital practioner
  Service Hématologie, CHU Poitiers
  Poitiers, France
• CD

  Caroline Dartigeas, MD

  Department of Haematology, University Hospital of Tours
  Tours, France
• RG

  Romain Guieze, MD, PhD

  Hematology department, Clermont-Ferrand University Hospital
  Clermont-Ferrand, France
• OT

  Olivier Tournilhac, MD, PhD

  Hematology department, Clermont-Ferrand University Hospital
  Clermont-Ferrand, France
• EF

  Emmanuelle Ferrant, MD

  Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie Clinique
  Pierre-Bénite, France
• Sd

  Sophie de Guibert, MD

  CHU Rennes, France
• PF

  Pierre Feugier, MD, PhD

  Inserm UMRS1256 Nutrition-Génétique et Exposition aux Risques Environnementaux (N-GERE), Université de Lorraine
  Nancy, France
• FM

  Fatiha Merabet, MD

  Department of Hematology and Oncology, Hôpital André Mignot
  Le Chesnay, France
• SL

  Stephane Lepretre, MD

  MD
  Centre Henri Becquerel
  Rouen, France
• PC

  Philippe Carassou, MD

  CHR Metz, France
• JG

  Julie Gay, MD

  Bayonne
  CH Cote Basque, France
• BH

  Benedicte Hivert, MD

  French Innovative Leukemia Organization, 87000
  Tonnellé, France
• LF

  Luc Matthieu Fornecker, MD, PhD

  CHU Strasbourg, France
• JD

  Jehan Dupuis, MD

  Lymphoid Malignancies Unit, Hôpital Henri Mondor, AP-HP
  Créteil, France
• LM

  Lysiane Molina, MD

  Hématologie clinique, CHU de Grenoble
  La Tronche, France
• BV

  Bruno Villemagne, MD

  Hematology Department, Centre Hospitalier Départemental
  La Roche sur Yon, France
• GC

  Guillaume Cartron, MD, PhD

  Head of Hematology Department
  Centre Hospitalier Universitaire de Montpellier
  Montpellier, France
• BD

  Bernard Drenou, MD

  GHRMSA
  Mulhouse, France
• BM

  Beatrice Mahe, MD

  Chu Nantes, France
• OB

  Omar Benbrahim, MD

  Chr Orleans, France
• XC

  Xavier Cahut, MD
• 

  Loic Ysebaert, MD, PhD

  Professor of Hematology
  IUCT Oncopole
  Toulouse, Midi-Pyrenees, France
• FN

  Florence Nguyen-Khac, MD, PhD

  Service d'Hématologie Biologique, Hôpital Pitié-Salpêtrière
  Paris, France
• VR

  Valerie Rouille, MD

  CHU Montpellier, France
• 

  Alain J. Delmer, MD, PhD

  Head
  Service Hématologie, CHU de Reims
  Reims, Champagne-Ardenne, France